… advanced non-small cell lung cancer (NSCLC) or melanoma … T cells against tumor-associated antigens. Tumors that were otherwise … to personalized neoantigen-based cancer vaccines, which are … 2 mRNA vaccines sensitize tumours to immune checkpoint blockade. …

… located—whether its breast cancer, lung cancer, or prostate cancer—tumor-agnostic therapy “transcends the … . DiscovHER PAN-206: phase 2 tumour-agnostic study of zanidatamab in …

… by lung cancer, cervical cancer, colorectal cancer, and liver cancer. These cancers account for … making. In cancer diagnosis, especially brain, lung, and breast tumors, this … cell spatial landscapes of the lung tumour immune microenvironment. Nature. …

… PhD, of Peter MacCallum Cancer Centre, in Melbourne, … lung cancer (NSCLC), anaplastic large cell lymphoma, and inflammatory myofibroblastic tumors … of Memorial Sloan Kettering Cancer Center (MSKCC), presented … -positive (ALK+) solid tumours. Ann Oncol. 2024 …

… divergence, resulting in profound tumor heterogeneity and therapy resistance. … CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013 … Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors …

… lung cancer (NSCLC), followed by head and neck cancer (HNC), esophageal cancer (EC), breast cancer … (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head … . Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a …

… than 0.5% of all lung tumors. Even while receiving treatment, she …

… than 0.5% of all lung tumours. Despite undergoing treatment, she continued …

… potential treatment options in breast cancer, lung cancer, genitourinary cancer, and many other patient … at the National Center for Tumor Diseases and part of the … , Pellatt AJ, et al. Circulating tumour DNA (ctDNA) clearance and correlation …

… with neoplastic diseases (including malignant lung tumours, haematological tumours, breast tumours, gynaecological …